Mr. Paul Duffy reports

AIML SUBSIDIARY NEURALCLOUD SIGNS BINDING COMMERCIAL TERM SHEET WITH VETMED CONSULTANTS FOR MAXYIELD ECG SERVICES

AI-ML Innovations Inc.'s wholly owned subsidiary, NeuralCloud Solutions Inc., signed a binding commercial term sheet and service level agreement, dated Sept. 25, 2026, with VetMed Consultants, Inc., a Santa Fe, N.M., preclinical cardiac safety consulting firm.

Under the agreement, the parties will follow a phased, gated pathway to evaluate whether NeuralCloud's MaxYield ECG signal-processing can support VetMed's preclinical cardiac safety and ECG analysis work for pharmaceutical sponsors and contract research organizations (CROs). The pathway begins with technical validation, followed by the build-out of data privacy, security and quality controls. VetMed will retain its client relationships, principal-investigator role, clinical adjudication and final scientific sign-off, while NeuralCloud will serve as a technology-enabled ECG processing and workflow partner.

VetMed provides preclinical trial consulting services for pharmaceutical companies and CROs. Its services include cardiology and ECG (electrocardiogram) evaluations, ECG validation and toxicology consultation in cardiology. The company works across electronic and paper-based study formats and operates under strict standard operating procedures consistent with current good laboratory practice guidelines.

Supporting preclinical cardiac safety workflows

The agreement is designed to validate MaxYield in supporting VetMed's ability to process ECG files more efficiently while preserving its expert clinical review and sponsor-facing authority. In the initial validation phase, NeuralCloud will process a set of anonymized ECG files supplied by VetMed using MaxYield.

MaxYield is NeuralCloud's proprietary ECG signal-processing engine. It is designed to improve ECG signal clarity, isolate and label waveform components, calculate ECG intervals, support arrhythmia detection and generate machine-readable outputs for downstream workflow use. In the VetMed engagement, NeuralCloud expects to evaluate and, subject to VetMed's validation and approval, adapt the MaxYield workflow for preclinical ECG data across multiple species and study formats.

Esmat Naikyar, president of NeuralCloud Solutions Inc. and chief product officer of AI-ML, commented: "VetMed is one of the most respected names in preclinical veterinary cardiology and cardiac safety. This agreement represents an important expansion of MaxYield into a high-value research and preclinical services environment. By combining VetMed's clinical authority with NeuralCloud's ECG signal-processing capabilities, our objective is to support faster, more consistent and more scalable ECG workflows while keeping expert cardiologist review at the center of the process."

About VetMed Consultants

VetMed is led by Dr. Larry P. Tilley, DVM, ACVIM, and Dr. Francis (Frank) W. K. Smith Jr., DVM, ACVIM, two highly regarded veterinary cardiology and internal medicine experts.

Together, Dr. Tilley and Dr. Smith bring more than three decades of toxicology consultation experience for pharmaceutical companies and CROs.

Dr. Tilley, president of VetMed Consultants, commented: "VetMed's work requires accuracy, consistency and deep clinical judgment and our findings must meet the regulatory expectations of our sponsors and the FDA. Before any new technology touches our sponsors' studies, it has to earn its place. This agreement is a structured research and validation effort: we will measure MaxYield's outputs against our own board-certified reads, interval by interval and species by species and we will confirm that data privacy, security and GLP-aligned controls are in place before anything moves toward operational use. If validated, a system like MaxYield could help make preclinical cardiac safety data more consistent and more reproducible, which could mean better decisions earlier in drug development and, ultimately, safer medicines for both animals and people."

Next steps

The agreement establishes a phased, gated framework. The parties will begin with technical verification and validation using representative ECG files across selected preclinical species and study formats. NeuralCloud will process supported files through MaxYield evaluate signal quality and ECG interval outputs and work with VetMed to confirm operational fit.

Following technical validation, the parties expect to move toward operational workflow integration, including file-format handling, quality review, reporting workflows and alignment with VetMed's existing study processes. This phase includes building a VetMed-dedicated environment with data-handling and audit-trail controls designed to comply with good laboratory practice standards, including applicable requirements of 21 CFR Part 58 and 21 CFR Part 11, under a security addendum agreed with VetMed, with U.S. data hosting where required by VetMed's sponsors. VetMed will remain responsible for final scientific and clinical adjudication, sponsor-facing reports and study sign-off.

Paul Duffy, executive chairman and chief executive officer of AIML, added: "This agreement provides an opportunity to evaluate MaxYield beyond traditional human clinical ECG workflows. Preclinical cardiac safety is a demanding, high-value environment where signal quality, consistency and expert review matter. Working with VetMed gives AIML exposure to an important pharmaceutical and CRO-facing market while allowing NeuralCloud to expand the application of its ECG signal-processing technology into multi-species preclinical research."

What MaxYield enables

In preclinical cardiac safety studies, ECG recordings can vary by species, acquisition method, file format and signal quality. MaxYield is designed to help standardize and structure ECG data by identifying waveform features, labelling key ECG components, calculating intervals and supporting quality review; however it has not yet been validated or tested by a third party for use with preclinical ECG data.

NeuralCloud's quality management system is certified to ISO 13485:2016 under the Medical Device Single Audit Program.

About AI-ML Innovations Inc.

AI-ML Innovations is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health.

We seek Safe Harbor.